StockData
Kazia Therapeutics Ltd logo

Kazia Therapeutics Ltd (KZIA) stock

KZIANasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Nov 17, 2026Score 1/30
$5.49+0.18 (+3.39%)

Close on Nov 18, 2026Market cap $8.89MP/E –Yield –

Kazia Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was A$7.33M, down 57.8% from the year before. The highest annual figure on record is A$20.17M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Jun 30, 2025A$7.33M-57.8%
FY2024Jun 30, 2024A$17.38M+11.7%
FY2023Jun 30, 2023A$15.56M-22.8%
FY2022Jun 30, 2022A$20.17M+38.7%
FY2021Jun 30, 2021A$14.54M+53.2%
FY2020Jun 30, 2020A$9.49M+46.6%
FY2019Jun 30, 2019A$6.48M-33.8%
FY2018Jun 30, 2018A$9.77M-12.2%
FY2017Jun 30, 2017A$11.14M+12.6%
FY2016Jun 30, 2016A$9.89M–

More Kazia Therapeutics figures

See a number that looks wrong?